ArticleScientific reports2018
CRISPR-Cas9, a tool to efficiently increase the development of recombinant African swine fever viruses.
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 83 citations in OpenAlex.
- CRISPR-Cas and Infectious Diseases: A Decade of Translational Advances in Molecular Biotechnology.Biochemical genetics · 2026Review
- Current Insights into the Epidemiology and Transmission Dynamics of African Swine Fever Virus and Future Control Perspectives.Pathogens (Basel, Switzerland) · 2026Review
- Advances in African swine fever vaccine development: challenges and prospects.Journal of veterinary science · 2026Review
- Establishment and characterization of a replication-restricted modified African swine fever virus.Microbiology spectrum · 2026Article
- African swine fever vaccine ASFV-G-ΔI177L induces solid protection in four-week-old piglets.Scientific reports · 2025Article
- The African swine fever virus MGF360-16R protein functions as a mitochondrial-dependent apoptosis inducer by competing with BAX to bind to the HSP60 protein.Journal of virology · 2025Article
- The Potential of Disabled Infectious Single Cycle (DISC) Virus Platforms for Next Generation African Swine Fever Vaccine Development.Transboundary and emerging diseases · 2025Review
- Lyophilization of ASFV vaccine candidate ASFV-G-ΔI177L offers long term stability.Scientific reports · 2024Article
- Article
- On-site detection and differentiation of African swine fever virus variants using an orthogonal CRISPR-Cas12b/Cas13a-based assay.iScience · 2024Article
- Article
- CA-CAS-01-A: A Permissive Cell Line for Isolation and Live Attenuated Vaccine Development Against African Swine Fever Virus.Journal of microbiology (Seoul, Korea) · 2024Article
- The Production of Recombinant African Swine Fever Virus Lv17/WB/Rie1 Strains and Their In Vitro and In Vivo Characterizations.Vaccines · 2023Article
- Advanced Strategies for Developing Vaccines and Diagnostic Tools for African Swine Fever.Viruses · 2023Review
- Review
- The 2022 Outbreaks of African Swine Fever Virus Demonstrate the First Report of Genotype II in Ghana.Viruses · 2023Article
- Deletion of theViruses · 2023Article
- Involvement of the MGF 110-11L Gene in the African Swine Fever Replication and Virulence.Vaccines · 2023Article
- Full genome sequence for the African swine fever virus outbreak in the Dominican Republic in 1980.Scientific reports · 2023Article
- Advances in CRISPR/Cas-Based Strategies on Zoonosis.Transboundary and emerging diseases · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
African swine fever virus (ASFV) causes a highly contagious disease called African swine fever. This disease is often lethal for domestic pigs, causing extensive losses for the swine industry. ASFV is a large and complex double stranded DNA virus. Currently there is no commercially available treatment or vaccine to prevent this devastating disease. Development of recombinant ASFV for producing live-attenuated vaccines or studying the involvement of specific genes in virus virulence has relied on the relatively rare event of homologous recombination in primary swine macrophages, causing difficulty to purify the recombinant virus from the wild-type parental ASFV. Here we present the use of the CRISPR-Cas9 gene editing system as a more robust and efficient system to produce recombinant ASFVs. Using CRISPR-Cas9 a recombinant virus was efficiently developed by deleting the non-essential gene 8-DR from the genome of the highly virulent field strain Georgia07 using swine macrophages as cell substrate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.